Vivian C. Chin

Array ( [id] => 16361060 [patent_doc_number] => 20200317811 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-08 [patent_title] => ANTI-COAGULATION FACTOR XI ANTIBODIES [patent_app_type] => utility [patent_app_number] => 16/864559 [patent_app_country] => US [patent_app_date] => 2020-05-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31311 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16864559 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17968280 [patent_doc_number] => 11485794 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-11-01 [patent_title] => Anti-coagulation factor XI antibodies [patent_app_type] => utility [patent_app_number] => 16/864577 [patent_app_country] => US [patent_app_date] => 2020-05-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 31 [patent_no_of_words] => 31088 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16864577 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16238279 [patent_doc_number] => 20200255513 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-13 [patent_title] => BINDING INHIBITOR BETWEEN TCTP DIMER TYPE IGE-DEPENDENT HISTAMINE RELEASING FACTOR AND RECEPTOR THEREOF, AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/862981 [patent_app_country] => US [patent_app_date] => 2020-04-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20308 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 41 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16862981 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18605892 [patent_doc_number] => 11747351 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-09-05 [patent_title] => Assays to monitor bleeding disorders [patent_app_type] => utility [patent_app_number] => 16/848445 [patent_app_country] => US [patent_app_date] => 2020-04-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 27 [patent_no_of_words] => 32903 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 102 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16848445 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18545310 [patent_doc_number] => 11718650 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-08-08 [patent_title] => Immunogenic peptides and their use in immune disorders [patent_app_type] => utility [patent_app_number] => 16/848086 [patent_app_country] => US [patent_app_date] => 2020-04-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 41 [patent_no_of_words] => 33794 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 136 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16848086 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17889766 [patent_doc_number] => 11452713 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-09-27 [patent_title] => Chemotherapeutic methods for treating low-proliferative disseminated tumor cells [patent_app_type] => utility [patent_app_number] => 16/845672 [patent_app_country] => US [patent_app_date] => 2020-04-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 48 [patent_no_of_words] => 8653 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 121 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16845672 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16361065 [patent_doc_number] => 20200317816 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-08 [patent_title] => REVERSAL BINDING AGENTS FOR ANTI-FACTOR XI/XIa ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/840031 [patent_app_country] => US [patent_app_date] => 2020-04-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 63237 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16840031 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16111667 [patent_doc_number] => 20200207856 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-02 [patent_title] => ANTIBODIES TO LILRB2 [patent_app_type] => utility [patent_app_number] => 16/815837 [patent_app_country] => US [patent_app_date] => 2020-03-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 49525 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16815837 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17609875 [patent_doc_number] => 20220152154 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-19 [patent_title] => GROWTH DIFFERENTIATION FACTOR 15 COMBINATION THERAPY [patent_app_type] => utility [patent_app_number] => 17/436696 [patent_app_country] => US [patent_app_date] => 2020-03-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16794 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17436696 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17625831 [patent_doc_number] => 20220160846 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-26 [patent_title] => CARBAMOYL PHOSPHATE SYNTHATASE-1 FOR THE TREATMENT AND PREVENTION OF INTERNAL TISSUE INJURY [patent_app_type] => utility [patent_app_number] => 17/433011 [patent_app_country] => US [patent_app_date] => 2020-02-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21406 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17433011 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16267396 [patent_doc_number] => 20200268883 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-27 [patent_title] => COMBINATIONS OF MODALITIES FOR THE TREATMENT OF DIABETES [patent_app_type] => utility [patent_app_number] => 16/800903 [patent_app_country] => US [patent_app_date] => 2020-02-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14155 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16800903 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18153119 [patent_doc_number] => 11566080 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-01-31 [patent_title] => Compositions and methods for treating IgE-mediated disorders [patent_app_type] => utility [patent_app_number] => 16/783032 [patent_app_country] => US [patent_app_date] => 2020-02-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 21 [patent_no_of_words] => 31298 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 84 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16783032 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16221321 [patent_doc_number] => 20200246437 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-06 [patent_title] => GENE THERAPY OF HEMOPHILIA B USING VIRAL VECTORS ENCODING RECOMBINANT FIX VARIANTS WITH INCREASED EXPRESSION [patent_app_type] => utility [patent_app_number] => 16/777630 [patent_app_country] => US [patent_app_date] => 2020-01-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 63475 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16777630 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16252180 [patent_doc_number] => 20200261554 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-20 [patent_title] => FACTOR IX POLYPEPTIDE FORMULATIONS [patent_app_type] => utility [patent_app_number] => 16/773634 [patent_app_country] => US [patent_app_date] => 2020-01-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16751 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16773634 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16221361 [patent_doc_number] => 20200246477 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-06 [patent_title] => ANTIBODY-DRUG CONJUGATE LYOPHILISED FORMULATION [patent_app_type] => utility [patent_app_number] => 16/742158 [patent_app_country] => US [patent_app_date] => 2020-01-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22345 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16742158 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15866331 [patent_doc_number] => 20200140569 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-07 [patent_title] => BINDING AGENT AND ASSAY FOR PIVKA [patent_app_type] => utility [patent_app_number] => 16/740778 [patent_app_country] => US [patent_app_date] => 2020-01-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20888 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 68 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16740778 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16112217 [patent_doc_number] => 20200208131 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-02 [patent_title] => PREPARATION OF FACTOR XA DERIVATIVES [patent_app_type] => utility [patent_app_number] => 16/740001 [patent_app_country] => US [patent_app_date] => 2020-01-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11815 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16740001 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15831979 [patent_doc_number] => 20200131271 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-04-30 [patent_title] => ANTIBODIES TO OPGL [patent_app_type] => utility [patent_app_number] => 16/738751 [patent_app_country] => US [patent_app_date] => 2020-01-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24242 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 53 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16738751 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16009313 [patent_doc_number] => 20200179499 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-11 [patent_title] => STRATEGIES TO PREVENT AND/OR TREAT IMMUNE RESPONSES TO SOLUBLE ALLOFACTORS [patent_app_type] => utility [patent_app_number] => 16/726411 [patent_app_country] => US [patent_app_date] => 2019-12-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14059 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16726411 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16406765 [patent_doc_number] => 10815308 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-10-27 [patent_title] => FIXaxFX bispecific antibody with common light chain [patent_app_type] => utility [patent_app_number] => 16/722452 [patent_app_country] => US [patent_app_date] => 2019-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 54 [patent_figures_cnt] => 44 [patent_no_of_words] => 51793 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 281 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16722452 [rel_patent_id] =>[rel_patent_doc_number] =>)